Navigation Links
BD and FIND Achieve Milestone in Global Battle Against MDR-TB
Date:6/23/2009

BD (Becton, Dickinson and Company; NYSE: BDX), a leading global medical technology company, and FIND (Foundation for Innovative New Diagnostics), a Swiss foundation that develops, evaluates and accelerates the implementation of new diagnostic tools for poverty-related diseases, today announced a significant price reduction in the cost of liquid culture testing for TB (Tuberculosis).

Oxford, UK and Geneva, Switzerland (PRWeb UK) June 23, 2009 -- BD (Becton, Dickinson and Company; NYSE: BDX), a leading global medical technology company, and FIND (Foundation for Innovative New Diagnostics), a Swiss foundation that develops, evaluates and accelerates the implementation of new diagnostic tools for poverty-related diseases, today announced a significant price reduction in the cost of liquid culture testing.

The agreement lowers the cost of BD MGIT™ reagents. BD's TB diagnostic technologies utilize liquid culture, a key "standard of care" TB testing protocol that provides results far faster than traditional, solid media culture. The liquid culture test, widely used in modern research settings, is particularly effective for stemming the spread of multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) in developing countries.

"By collaborating with such leading global health organizations as FIND, BD's Global Health initiative implements diagnostic programs that help strengthen healthcare infrastructures in developing countries," said Krista Thompson, Vice President and General Manager, Global Health, BD. "With an emphasis on accessibility, affordability and sustainability, BD provides on-the-ground technical assistance, training and products that maximize the capacity to diagnose TB, including drug-resistant strains, in nations where the disease is most prevalent."

The price reduction -- announced five months earlier than anticipated -- arises from a November 2007 agreement between BD and FIND. At that time, BD agreed to reduce already below-market prices upon the completion of 3.5 million tests, a milestone achieved this month. The lower prices will enable more tests to be administered in 39 high-burden countries, as identified by the World Health Organization (WHO).

"We are very happy about this price reduction for a needed assay to better and more rapidly detect MDR-TB and XDR-TB. These results are also a direct outcome of a fruitful collaboration with public and private partners such as UNITAID and BD," said Dr. Giorgio Roscigno, FIND Chief Executive Officer. "During a time of severe economic distress, resources are constrained and high-burden countries face intensified healthcare challenges. This agreement means that it will be possible to make this test more accessible and affordable to those who need it most, which is very encouraging and promising."

"With financial support from UNITAID, state-of-the-art technologies to diagnose MDR-TB are being introduced in low-income countries for the first time by FIND, GLI and GDF," said Jorge Bermudez, Executive Secretary of UNITAID. "UNITAID has also approved the expansion of the project with a new grant of US $61 million to extend access to these superior tests to an additional 11 high burden countries."

Under the terms of the agreement, the reagents will now be discounted 80%. Slight price variations will occur for end users because of shipping costs, tariffs, fees and other local costs that vary from country to country. The agreement provides for potential added discounts as test tube volume expands.    

BD and FIND said they were able to accelerate the program with the help of financial support from a consortium consisting of UNITAID, the Global Laboratory Initiative and Global Drug Facility, along with FIND itself.

Over the next four years it is expected that partners GDF, GLI and FIND will provide equipment, reagents and technical expertise in identified countries for modernizing and expanding TB laboratory diagnostic capacity.

FIND and BD had announced the initial pricing agreement in November 2007 shortly after the WHO's Strategic and Technical Advisory Group for TB recommended liquid culture technology based on demonstration studies conducted by FIND in eight countries.

BD and FIND announced the price reduction today at the Pacific Health Summit, which is held annually in Seattle, WA. The Summit's 2009 theme is "MDR-TB: Overcoming Global Resistance."

About FIND
FIND, based in Geneva, Switzerland, is a not-for-profit Swiss foundation whose mission is to drive the development and implementation of accurate and affordable diagnostic tests that can be used as near as possible to where patients first seek care. FIND's disease portfolio currently includes tuberculosis, malaria and human African trypanosomiasis and current donors are the Bill & Melinda Gates Foundation, the European Union, the Government of the Netherlands, UNITAID, Irish Aid and other institutions and private donors. FIND is ISO 9001:2000 and ISO 13485:2003 certified. For more information, please visit: http://www.finddiagnostics.org.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving
people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com/uk.

###

Read the full story at http://www.prweb.com/releases/2009/06/prweb2562614.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
2. Kaiser Permanente Achieves Climate Action Leader Status
3. Computer models help raise the bar for sporting achievement
4. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
5. OSF HealthCare Achieves Impressive Tobacco Quit Rates with the Free & Clear(R) Quit For Life(TM) Program
6. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
7. Smurfit-Stones Hodge, LA, Mill Becomes First to Achieve Safety Milestone
8. Batters may achieve dramatic increases in home runs through steroids
9. Wyeths Pearl River, N.Y. Facility Celebrates 100 Years of Achievements in Health care
10. LMS integrated obstetrics solution achieves general availability
11. Nations Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... York, New York (PRWEB) , ... January 24, 2017 , ... ... for Brazilian butt lifts is on the rise. According to the American Society ... augmentations since 2000. On average, these procedures are performed every 30 minutes of every ...
(Date:1/24/2017)... PA (PRWEB) , ... January 24, 2017 , ... ... showcase its newest technology offering, Processing Assurance Control Equipment (PACE), at the International ... 2, 2017. , PeroxyChem’s booth will highlight the new technology that is used ...
(Date:1/24/2017)... ... January 24, 2017 , ... Twelve startups have been ... 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour Founder and CEO Kevin ... will showcase their businesses on February 6, 2017, at Under Armour’s global headquarters ...
(Date:1/24/2017)... ... January 24, 2017 , ... Bellus Medical, a leader in medical aesthetics, today ... his new role Dr. Dobke will provide physician oversight for in-house clinical studies and ... of Plastic Surgery and Associate Professor of Surgery at UC San Diego Health and ...
(Date:1/24/2017)... ... January 24, 2017 , ... Inspiration, ... , Well-meaning studies such as the Fordham Institute’s High Stakes for High ... students, such as including gifted or high-achieving students as a subgroup and reporting ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)...  In a major study released this weekend ... 1 ( http://www.multivu.com/players/English/7899551-nephrocheck-test-acute-kidney-injury-outcomes/ ), Astute ... identified patients at high risk of Acute Kidney ... randomized control trial led by Alexander Zarbock ... institution,s standard of care or a treatment per ...
(Date:1/24/2017)... Jan. 24, 2017 Data4Cure, Inc. today announced ... its Biomedical Intelligence® Cloud - a semantic data-driven discovery ... of genomic, molecular and clinical data that are accumulating ... a session hosted by Data4Cure at the Precision Medicine ... The company,s Biomedical Intelligence® Cloud ...
(Date:1/24/2017)... , Jan. 24, 2017 Regeneron Pharmaceuticals, Inc. ... Public today recognized 40 finalists in the Regeneron Science ... and math competition for high school seniors. Finalists were ... of their research projects. The finalists will ... from March 9-15 to undergo a rigorous judging process ...
Breaking Medicine Technology: